Lymphoid myelofibrosis represents an anatomoclinical syndrome of constant symptomatology characterized predominantly by splenomegaly, few lymphadenopathies, pancytopenia with blood lymphocytosis, and a hypoplastic myelogram comprising lymphocytes and histiocytes. Histological study of bone marrow biopsy shows association of lymphoid proliferation as well as network cell proliferation, giving rise to a dense lattice of reticulum and collagen fibers, without osteosclerosis. The cytology of the syndrome and its relationship to lymphoid leukemia, Waldenström’s disease and those syndromes termed reticuloendotheliosis or malignant histiocytosis is discussed. It is not easy to evaluate the efficiency of therapeutic measures, since myelofibrosis precludes that kind of chemotherapy as is currently used in lymphoproliferative syndromes; therefore, prognosis is incertain although clinical evolution is slow

Keywords:
Bone marrow biopsy, Lymphoid myelofibrosis, Myelofibrosis, Pancytopenia, Reticulosis
This content is only available via PDF.
© 1971 S. Karger AG, Basel
1971
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.